To Assess Safety, Reactogenicity and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine, Co-admin With GSK Biologicals' MMRV Vaccine in Children (2nd yr of Life) Primed With the Pneumococcal Conjugate Vaccine in Study 105553. [EXTENSION OF 700016817]

Trial Profile

To Assess Safety, Reactogenicity and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine, Co-admin With GSK Biologicals' MMRV Vaccine in Children (2nd yr of Life) Primed With the Pneumococcal Conjugate Vaccine in Study 105553. [EXTENSION OF 700016817]

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Hib-DTaP-hepatitis B-poliovirus vaccine; MMR-varicella zoster virus vaccine
  • Indications Chickenpox; Diphtheria; Hepatitis B; Measles; Mumps; Pertussis; Pneumococcal infections; Poliomyelitis; Tetanus
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 03 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top